Chemistry:Fadolmidine
Fadolmidine (development code MPV-2426) is an experimental α2 adrenergic receptor agonist that has been investigated as a spinal analgesic. It was developed with the aim of providing antinociceptive effects with reduced systemic side effects compared to other α2 agonists.[1]
Pharmacology
Fadolmidine acts as a selective α2 adrenergic receptor agonist, a receptor class associated with modulation of nociceptive signalling. A 2004 review described preclinical evidence of spinal antinociceptive effects in laboratory models and suggested a reduced propensity for sedation compared with systemic α2 agonists.[1]
Development
The compound was developed under the code MPV-2426. As of 2025, it has no approved medical indication and has not advanced to late-stage clinical development.[2]
Chemistry
Fadolmidine is an imidazole-derived compound structurally related to other α2 agonists such as medetomidine and dexmedetomidine.[1]
References
- ↑ 1.0 1.1 1.2 "Antinociceptive properties of fadolmidine (MPV-2426), a novel alpha2-adrenoceptor agonist". CNS Drug Reviews 10 (2): 117–126. 2004. doi:10.1111/j.1527-3458.2004.tb00008.x. PMID 15179442.
- ↑ "Fadolmidine". AdisInsight. Springer Nature. https://adisinsight.springer.com/drugs/800013220.
 |  |
